Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III lot-to-lot consistency study of HZ/su herpes zoster vaccine in adults aged 50 years and older
2013-000373-76Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Zoster vaccine recombinant in herpes zoster (HZ) (3 arms), sponsored by GSK. Primary endpoint: Anti-gE humoral immunogenicity. Started Dec 2013; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2013-000373-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000373-76.